Rosalind Advisors Inc. 13D and 13G filings for MediWound Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-11 12:59 pm Unchanged | 2025-12-31 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 912,319 7.000% | 0 (Unchanged) | Filing |
| 2025-11-12 11:42 am Purchase | 2025-09-30 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 912,319 7.000% | 341,993![]() (+59.96%) | Filing |
| 2025-08-12 11:40 am Sale | 2025-06-30 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 570,326 5.200% | -99,832![]() (-14.90%) | Filing |
| 2025-05-12 2:45 pm Sale | 2025-03-31 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 670,158 6.100% | -121,157![]() (-15.31%) | Filing |
| 2025-02-11 4:18 pm Purchase | 2024-12-31 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 791,315 7.200% | 163,265![]() (+26.00%) | Filing |
| 2024-10-23 2:57 pm Purchase | 2024-09-30 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 628,050 5.800% | 114,560![]() (+22.31%) | Filing |
| 2024-07-11 5:43 pm Purchase | 2024-06-28 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 513,490 7.160% | 27,500![]() (+5.66%) | Filing |
| 2024-04-25 7:22 pm Purchase | 2024-03-31 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 485,990 6.920% | 6,000![]() (+1.25%) | Filing |
| 2024-02-14 8:48 pm Purchase | 2023-12-31 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 479,990 5.200% | 479,990![]() (New Position) | Filing |
| 2024-02-14 8:43 pm Purchase | 2023-12-31 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 479,990 5.200% | 35,664![]() (+8.03%) | Filing |
| 2022-12-21 12:37 pm Purchase | 2022-12-02 | 13G | MediWound Ltd. MDWD | Rosalind Advisors Inc. | 444,326 6.100% | 444,326![]() (New Position) | Filing |

